Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
Cancer Medicine|March 18, 2021
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysisMax S Topp, Anthony S Stein, Nicola Gökbuget, et al.
Blood Advances|June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaAnthony S Stein, Richard A Larson, Andre C Schuh, et al.
The Journal of Clinical Investigation|August 22, 2002
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virusDavid M Koelle, Zhi Liu, Christopher M McClurkan, et al.
Immunology and Cell Biology|May 14, 2014
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and miceTanja Bedke, Rossana G Iannitti, Antonella De Luca, et al.
Journal of Leukocyte Biology|August 13, 2015
Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases TregsCarsten Berges, Tanja Bedke, Claudia Stuehler, et al.
Experimental Hematology & Oncology|May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLVirginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.
Haematologica|February 8, 2020
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphomaMax S Topp, Johannes Duell, Ana Maria Abajo Guijarro, et al.
Haematologica|February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6Leo Rasche, Johannes Duell, Inês C Castro, et al.
Blood|December 3, 2005
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatusOlaf Beck, Max S Topp, Ulrike Koehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin LymphomaBastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Cancer Medicine|March 18, 2021
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysisMax S Topp, Anthony S Stein, Nicola Gökbuget, et al.
Blood Advances|June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaAnthony S Stein, Richard A Larson, Andre C Schuh, et al.
The Journal of Clinical Investigation|August 22, 2002
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virusDavid M Koelle, Zhi Liu, Christopher M McClurkan, et al.
Immunology and Cell Biology|May 14, 2014
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and miceTanja Bedke, Rossana G Iannitti, Antonella De Luca, et al.
Journal of Leukocyte Biology|August 13, 2015
Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases TregsCarsten Berges, Tanja Bedke, Claudia Stuehler, et al.
Experimental Hematology & Oncology|May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLVirginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.
Haematologica|February 8, 2020
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphomaMax S Topp, Johannes Duell, Ana Maria Abajo Guijarro, et al.
Haematologica|February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6Leo Rasche, Johannes Duell, Inês C Castro, et al.
Blood|December 3, 2005
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatusOlaf Beck, Max S Topp, Ulrike Koehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin LymphomaBastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Pageof 13